TAYSHA GENE THERAPIES INC (TSHA) — insider trading
Health Care · NASDAQ
TAYSHA GENE THERAPIES INC (TSHA) has 23 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 23 (latest 2026-07-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar | Director, Officer (President and Head of R&D) | Open-market sale | 200,000 | $6.24 | $1.25M | Form 4 |
| 2026-06-01 | Sepp-Lorenzino Laura | Director | Grant / award / vesting (derivative) | 42,671 | — | $0 | Form 4 |
| 2026-06-01 | Sepp-Lorenzino Laura | Director | Grant / award / vesting | 21,335 | — | $0 | Form 4 |
| 2026-06-01 | Long Alison S | Director | Grant / award / vesting (derivative) | 42,671 | — | $0 | Form 4 |
| 2026-06-01 | Long Alison S | Director | Grant / award / vesting | 21,335 | — | $0 | Form 4 |
| 2026-06-01 | Donenberg Phillip B. | Director | Grant / award / vesting (derivative) | 42,671 | — | $0 | Form 4 |
| 2026-06-01 | Donenberg Phillip B. | Director | Grant / award / vesting | 21,335 | — | $0 | Form 4 |
| 2026-06-01 | Stalfort John A III | Director | Grant / award / vesting (derivative) | 42,671 | — | $0 | Form 4 |
| 2026-06-01 | Stalfort John A III | Director | Grant / award / vesting | 21,335 | — | $0 | Form 4 |
| 2026-04-10 | Nagendran Sukumar | Director, Officer (President and Head of R&D) | Option exercise / conversion (derivative) | 19,021 | — | $0 | Form 4 |
| 2026-04-10 | Nagendran Sukumar | Director, Officer (President and Head of R&D) | Open-market sale | 200,000 | $4.46 | $892.0K | Form 4 |
| 2026-04-10 | Nagendran Sukumar | Director, Officer (President and Head of R&D) | Option exercise / conversion | 19,021 | $1.71 | $32.5K | Form 4 |
| 2026-02-04 | Alam Kamran | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 1,655 | $4.52 | $7.5K | Form 4 |
| 2026-01-26 | Alam Kamran | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 23,849 | $4.61 | $109.9K | Form 4 |
| 2026-01-26 | Nolan Sean P. | Director, Officer (Chief Executive Officer) | Open-market sale | 41,312 | $4.61 | $190.4K | Form 4 |
| 2026-01-26 | Nagendran Sukumar | Director, Officer (President and Head of R&D) | Open-market sale | 26,918 | $4.61 | $124.1K | Form 4 |
| 2026-01-23 | Alam Kamran | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 78,968 | $4.75 | $375.1K | Form 4 |
| 2026-01-23 | Nolan Sean P. | Director, Officer (Chief Executive Officer) | Open-market sale | 136,789 | $4.75 | $649.7K | Form 4 |
| 2026-01-23 | Nagendran Sukumar | Director, Officer (President and Head of R&D) | Open-market sale | 89,132 | $4.75 | $423.4K | Form 4 |
| 2026-01-12 | Nolan Sean P. | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 648,000 | — | $0 | Form 4 |
| 2026-01-12 | Nolan Sean P. | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 1,008,000 | — | $0 | Form 4 |
| 2026-01-12 | Alam Kamran | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 231,000 | — | $0 | Form 4 |
| 2026-01-12 | Alam Kamran | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting | 359,000 | — | $0 | Form 4 |
Ask the chat about TSHA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TAYSHA GENE THERAPIES INC (TSHA).
Last updated 2026-07-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.